Experienced in Angioplasty

Dr. Saravanan Balamuthusamy

Fort Worth, TX
Experienced
in Angioplasty
Specialties:Nephrology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Saravanan Balamuthusamy is a Nephrologist in Fort Worth, Texas. Dr. Balamuthusamy and is rated as an Experienced provider by MediFind in Angioplasty. His top areas of expertise are End-Stage Renal Disease (ESRD), Chronic Kidney Disease, Von Gierke Disease, Angioplasty, and Endoscopy. Dr. Balamuthusamy is currently accepting new patients.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 1 clinical trial in the study of Angioplasty.

Specialties
Nephrology
Licenses
Internal Medicine in LA
Hospital Affiliations
Texas Health Harris Methodist Hospital Southwest F
Medical City Fort Worth
Texas Health Harris Methodist Hospital Fort Worth
Languages Spoken
English
Tamil
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Friday Health
  •  Oscar
  •  Humana

Locations

PPG HEALTH PA
1001 Pennsylvania Ave, Fort Worth, TX 76104
817-877-5907

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy
A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy
Enrollment Status: Active_not_recruiting
Publish Date: November 18, 2024
Intervention Type: Drug
Study Drugs: Sparsentan, Irbesartan
Study Phase: Phase 3
A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy
A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2024
Intervention Type: Drug
Study Drug: BION-1301
Study Phase: Phase 1/Phase 2
A Repeat Dose, Open Label, Two Period, Randomized, Cross Over Study to Compare the Effect of Daprodustat to Recombinant, Human Erythropoietin (rhEPO) on Oral Iron Absorption in Adult Participants With Anemia Associated With Chronic Kidney Disease Who Are Not on Dialysis
A Repeat Dose, Open Label, Two Period, Randomized, Cross Over Study to Compare the Effect of Daprodustat to Recombinant, Human Erythropoietin (rhEPO) on Oral Iron Absorption in Adult Participants With Anemia Associated With Chronic Kidney Disease Who Are Not on Dialysis
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Drug
Study Drugs: Daprodustat, Epoetin Alpha, Ferrous Sulfate
Study Phase: Phase 2
Prospective, Randomized, Controlled, Multicenter Study Comparing the Merit WRAPSODY™ Endovascular Stent Graft to Percutaneous Transluminal Angioplasty for Treatment of Venous Outflow Circuit Stenosis or Occlusion in Hemodialysis Patients. The WAVE Study
Prospective, Randomized, Controlled, Multicenter Study Comparing the Merit WRAPSODY™ Endovascular Stent Graft to Percutaneous Transluminal Angioplasty for Treatment of Venous Outflow Circuit Stenosis or Occlusion in Hemodialysis Patients. The WAVE Study
Enrollment Status: Active_not_recruiting
Publish Date: March 22, 2024
Intervention Type: Device
Study Phase: Not Applicable
View 3 Less Clinical Trials

22 Total Publications

Six-month safety and efficacy outcomes from the randomized-controlled arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial.
Six-month safety and efficacy outcomes from the randomized-controlled arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial.
Journal: Kidney international
Published: July 25, 2024
Similar Doctors
Expertise in
3
conditions
Dr. Christopher A. Hebert
Nephrology
Expertise in
3
conditions
Dr. Christopher A. Hebert
Nephrology
3900 Junius St, Suite 615, 
Dallas, TX 
 (32.6 mi)
972-388-5970
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Christopher Hebert is a Nephrologist in Dallas, Texas. Dr. Hebert and is rated as an Advanced provider by MediFind in Angioplasty. His top areas of expertise are End-Stage Renal Disease (ESRD), Chronic Kidney Disease, Acute Kidney Failure, Stent Placement, and Angioplasty. Dr. Hebert is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile